低正常与高正常氧合目标对危重患者器官功能障碍的影响:一项随机临床试验
该多中心随机临床试验在荷兰4个ICU纳入574例符合2项及以上SIRS标准且预期停留超过48小时的成人患者,比较低正常PaO2目标(8-12 kPa)与高正常目标(14-18 kPa)对器官功能障碍的影响。
要点
- 在伴有SIRS的危重患者中,低正常PaO2目标较高正常目标未显著减少器官功能障碍。
- 两组机械通气时长和院内死亡率无显著差异。
- 低正常组轻度低氧测量发生率更高,需关注低氧风险。
核心结论
- 在符合2项及以上SIRS标准的危重患者中,低正常PaO2目标较高正常目标未导致器官功能障碍的统计学显著减少。
- 研究可能把握度不足以检测比假设更小的治疗效应。
研究设计与样本
- 多中心随机临床试验,在荷兰4个ICU开展,入组时间为2015年2月至2018年10月,随访至2019年1月。
- 纳入成人患者需符合2项及以上SIRS标准且预期ICU停留超过48小时。
- 共筛选9925例患者,574例符合标准并随机分组,其中400例(70%)在24小时内入组,中位年龄68岁,女性140例(35%),全部完成试验。
- 干预目标PaO2范围:低正常组8-12 kPa(n=205),高正常组14-18 kPa(n=195)。
- 仅在有临床指征时应用吸入氧浓度大于0.60。
主要发现
- 两组间中位PaO2差异为-1.93 kPa(95%CI,-2.12至-1.74;P<.001)。
- 低正常组中位SOFARANK评分为-35分,高正常组为-40分,中位差异10(95%CI,0至21;P=.06)。
- 中位机械通气时长低正常组3.4天 vs 高正常组3.1天,中位差异-0.15(95%CI,-0.88至0.47;P=.59)。
- 院内死亡率低正常组32% vs 高正常组31%,比值比1.04(95%CI,0.67至1.63;P=.91)。
- 轻度低氧测量低正常组发生率1.9% vs 高正常组1.2%,中位差异0.73(95%CI,0.30至1.20;P<.001);急性肾衰竭低正常组20例(10%) vs 高正常组21例(11%),急性心肌梗死低正常组6例(2.9%) vs 高正常组7例(3.6%)。
临床怎么用
- 对于符合2项及以上SIRS标准的危重患者,采用低正常PaO2目标(8-12 kPa)未显著改善非呼吸器官功能障碍,且轻度低氧更常见。
- 临床决策时需权衡低正常氧合目标的潜在获益与低氧风险,高正常目标未显示劣势。
局限性
- 研究可能把握度不足,无法检测比假设更小的治疗效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hyperoxemia may increase organ dysfunction in critically ill patients, but optimal oxygenation targets are unknown. OBJECTIVE: To determine whether a low-normal Pao2 target compared with a high-normal target reduces organ dysfunction in critically ill patients with systemic inflammatory response syndrome (SIRS). DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial in 4 intensive care units in the Netherlands. Enrollment was from February 2015 to October 2018, with end of follow-up to January 2019, and included adult patients admitted with 2 or more SIRS criteria and expected stay of longer than 48 hours. A total of 9925 patients were screened for eligibility, of whom 574 fulfilled the enrollment criteria and were randomized. INTERVENTIONS: Target Pao2 ranges were 8 to 12 kPa (low-normal, n = 205) and 14 to 18 kPa (high-normal, n = 195). An inspired oxygen fraction greater than 0.60 was applied only when clinically indicated. MAIN OUTCOMES AND MEASURES: Primary end point was SOFARANK, a ranked outcome of nonrespiratory organ failure quantified by the nonrespiratory components of the Sequential Organ Failure Assessment (SOFA) score, summed over the first 14 study days. Participants were ranked from fastest organ failure improvement (lowest scores) to worsening organ failure or death (highest scores). Secondary end points were duration of mechanical ventilation, in-hospital mortality, and hypoxemic measurements. RESULTS: Among the 574 patients who were randomized, 400 (70%) were enrolled within 24 hours (median age, 68 years; 140 women [35%]), all of whom completed the trial. The median Pao2 difference between the groups was -1.93 kPa (95% CI, -2.12 to -1.74; P < .001). The median SOFARANK score was -35 points in the low-normal Pao2 group vs -40 in the high-normal Pao2 group (median difference, 10 [95% CI, 0 to 21]; P = .06). There was no significant difference in median duration of mechanical ventilation (3.4 vs 3.1 days; median difference, -0.15 [95% CI, -0.88 to 0.47]; P = .59) and in-hospital mortality (32% vs 31%; odds ratio, 1.04 [95% CI, 0.67 to 1.63]; P = .91). Mild hypoxemic measurements occurred more often in the low-normal group (1.9% vs 1.2%; median difference, 0.73 [95% CI, 0.30 to 1.20]; P < .001). Acute kidney failure developed in 20 patients (10%) in the low-normal Pao2 group and 21 patients (11%) in the high-normal Pao2 group, and acute myocardial infarction in 6 patients (2.9%) in the low-normal Pao2 group and 7 patients (3.6%) in the high-normal Pao2 group. CONCLUSIONS AND RELEVANCE: Among critically ill patients with 2 or more SIRS criteria, treatment with a low-normal Pao2 target compared with a high-normal Pao2 target did not result in a statistically significant reduction in organ dysfunction. However, the study may have had limited power to detect a smaller treatment effect than was hypothesized. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02321072.
引用
- Gelissen H, de Grooth HJ, Smulders Y, et al. Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial. JAMA. 2021. PMID: 34463696. doi:10.1001/jama.2021.13011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。